Gilead will begin charging U.S. patients for the experimental COVID-19 drug remdesivir in two weeks, the company and the government announced Monday, as cases surge and hospitalizations reach crisis levels…

Read more »

The post Gilead Says It Will Charge $3,120 Per Patient for COVID-19 Drug appeared first on Hamodia.

In related news:

  1. Gilead Prices COVID-19 Drug Candidate Remdesivir at $2,340/Patient
  2. Gilead’s Remdesivir Meets Main Goal of Trial in COVID-19 Patients
  3. Coronavirus Patients Rush to Join Studies of Gilead Drug
  4. Gilead Faces Lawsuit Over Hepatitis C Drug Pricing
  5. Gilead Disputes Report That Its Drug Flopped in Coronavirus Trial